Enliven Therapeutics (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,500 Shares

Key Points

• CEO Samuel Kintz of Enliven Therapeutics sold 12,500 shares at an average price of $21.33, totaling $266,625, which decreased his ownership by 1.37%.
• Following the sale, Kintz still holds 902,892 shares in the company, valued at approximately $19.26 million.
• Enliven Therapeutics has seen a 4.2% decline in stock price, trading at $21.19, with analysts giving a consensus price target of $41.20 and a moderate buy rating.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $21.33, for a total transaction of $266,625.00. Following the transaction, the chief executive officer directly owned 902,892 shares in the company, valued at $19,258,686.36. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Samuel Kintz also recently made the following trade(s):

• On Friday, September 26th, Samuel Kintz sold 3,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.06, for a total transaction of $74,222.00.
• On Tuesday, September 23rd, Samuel Kintz sold 2,800 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.03, for a total transaction of $56,084.00.
• On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.25, for a total transaction of $20,250.00.
• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.09, for a total transaction of $95,450.00.
• On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $11,800.00.
• On Monday, August 18th, Samuel Kintz sold 10,393 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.02, for a total transaction of $208,067.86.

Enliven Therapeutics Trading Down 4.2%

ELVN stock traded down $0.93 during trading on Tuesday, reaching $21.19. 435,583 shares of the stock were exchanged, compared to its average volume of 402,015. The business has a 50 day moving average price of $20.12 and a 200-day moving average price of $19.62. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $29.78. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -10.60 and a beta of 0.85.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ELVN. GAMMA Investing LLC grew its holdings in shares of Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after purchasing an additional 2,630 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Enliven Therapeutics by 4.5% in the first quarter. Bank of New York Mellon Corp now owns 93,567 shares of the company's stock valued at $1,841,000 after purchasing an additional 3,992 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $430,000. BIT Capital GmbH acquired a new position in Enliven Therapeutics during the 1st quarter worth approximately $382,000. Finally, Invesco Ltd. grew its holdings in Enliven Therapeutics by 39.6% during the 1st quarter. Invesco Ltd. now owns 21,044 shares of the company's stock worth $414,000 after acquiring an additional 5,972 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Analyst Ratings Changes

ELVN has been the subject of a number of recent analyst reports. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.